LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mitochondrial Protein Linked to Development of Prostate Cancer

By Gerald M. Slutzky, PhD
Posted on 23 Nov 2016
Image: A micrograph of prostate adenocarcinoma, acinar type, the most common type of prostate cancer (Photo courtesy of Wikimedia Commons).
Image: A micrograph of prostate adenocarcinoma, acinar type, the most common type of prostate cancer (Photo courtesy of Wikimedia Commons).
Results obtained from experiments with genetically engineered mouse models revealed a direct link between the mitochondrial chaperone protein, TRAP1 (TNF receptor associated protein 1) and the development of prostate cancer.

TRAP1 is a chaperone protein that is structurally similar to heat shock protein 90 (HSP90), which is found in elevated levels in the mitochondria of cancer cells. In a prior study, investigators at The Wistar Institute (Philadelphia, PA, USA) genetically engineered a line of mice with the gene for TRAP1 protein "knocked out" to determine what impact it may have on disease. They found that these mice lived longer and experienced fewer age-related illnesses than did normal animals.

In the current study, the investigators created a line of mice that overexpressed the TRAP1 gene. Furthermore, these animals also lacked one copy of the important tumor suppressor gene PTEN. At least one copy of PTEN is deleted in about 40% of cases of prostate cancer and is often found in more aggressive tumors, so mice without this gene more accurately simulate the behavior of the disease.

The investigators reported in the October 17, 2016, online edition of the Journal of Biological Chemistry that combination of increased TRAP1 coupled with the loss of PTEN resulted in the development of aggressive, early-onset invasive prostate cancer. The mice also displayed increased tumor cell proliferation, inhibition of apoptosis, and increased epithelial cell invasion.

"In our prior study, while we had evidence that hinted at TRAP1's role in tumor growth, we lacked the direct evidence we needed to define the role of this protein in prostate cancer development," said senior author Dr. Dario C. Altieri, president and CEO of The Wistar Institute. "As we better understand the role of mitochondria in cancer, it's important to thoroughly study the roles of the proteins involved in helping tumors receive the energy they desire for survival. What is exciting about these findings is the fact that we believe TRAP1 is a druggable target. We are continuing to advance our promising research and development program aimed at targeting the mitochondria in tumors."

Related Links:
The Wistar Institute


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more